Enhanced Recovery After Surgery (ERAS) Increases Long-Term Survival Rate after Surgery in Colorectal Cancer Patients: A Systematic Review and Meta-Analysis

This systematic review and meta-analysis demonstrates that Enhanced Recovery After Surgery (ERAS) protocols significantly improve 1- to 5-year overall survival and reduce long-term mortality in colorectal cancer patients, particularly among those with early-stage tumors and high adherence to the protocol, although no statistically significant benefit was observed for disease-free survival.

The Gist

Imagine your body is a high-performance race car. When a surgeon operates on a patient with colorectal cancer, it's like taking that car apart to fix a critical engine issue. In the past, the standard way of doing this was to let the car sit in the garage for a long time, let the engine cool down completely, and only start it up again very slowly after the repair. This "conventional care" often left the car (the patient) feeling sluggish, prone to breakdowns (complications), and taking a long time to get back on the road.

Enter ERAS (Enhanced Recovery After Surgery). Think of ERAS as a modern, high-tech pit crew strategy. Instead of letting the car idle, the pit crew (the medical team) prepares the car before the race, uses precise tools during the repair, and gets the engine running smoothly immediately after. They use better fuel (nutrition), keep the engine warm (temperature control), and minimize the shock to the system (less pain medication, early movement).

This paper asks a big question: Does this "pit crew strategy" not only get the car back on the road faster, but does it also help the car last longer over the next 5, 10, or 20 years?

Here is the breakdown of what the researchers found, using simple analogies:

1. The Big Discovery: It's Not Just About Speed; It's About Longevity

For a long time, doctors knew ERAS helped patients recover quickly from surgery (shorter hospital stays, less pain). But they weren't sure if it actually helped them live longer in the long run.

This study looked at 10 different research reports involving nearly 6,000 patients. It's like gathering data from 10 different race tracks to see if the pit crew strategy actually wins more championships over a decade.

The Result: Yes! Patients who followed the ERAS "pit crew" plan lived significantly longer.

• The Analogy: If you have 100 patients, the ERAS group had fewer deaths at 1, 2, 3, and even 5 years compared to the group that got standard care.
• The Stat: The risk of dying in the long term was cut by 28%. That's a huge difference, like reducing the chance of a car breaking down by nearly a third.

2. The "Adherence" Factor: You Have to Follow the Manual

The study found that the benefits weren't just about having the plan; they were about following the plan.

• The Analogy: Imagine a recipe for a perfect cake. If you have the recipe (the ERAS protocol) but you skip steps—like not preheating the oven or forgetting the sugar—the cake won't turn out right.
• The Finding: Patients who followed 70% or more of the ERAS steps got the biggest survival boost. Patients who only followed a few steps didn't see as much benefit.
• The Lesson: It's not enough to just say "we do ERAS." The medical team has to actually execute the steps (like getting the patient eating and walking the same day) to get the long-term survival prize.

3. The "Early Stage" Advantage

The study also looked at who benefited the most.

• The Analogy: Think of cancer as a small leak in a boat. If you catch it early (Stage I or II) and patch it up with the best tools (ERAS), the boat is much more likely to stay afloat for a long time. If the leak is huge and the boat is already taking on water (Stage III or IV), the patch helps, but the odds are tougher.
• The Finding: Patients with early-stage cancer saw the most dramatic improvement in survival rates when using ERAS.

4. The One Mystery: "Disease-Free" vs. "Alive"

The study found something interesting that needs a bit of explanation.

• Overall Survival (OS): ERAS definitely helped patients stay alive.
• Disease-Free Survival (DFS): ERAS did not show a statistically significant difference in keeping the cancer from coming back (recurrence).

Why the difference?

• The Analogy: Imagine two drivers. Driver A (ERAS) recovers from a crash so well that their body stays strong and they can fight off future storms. Driver B (Standard Care) is weak after the crash. Even if the car (the cancer) is the same for both, Driver A is more likely to survive the next few years because their body is in better shape to handle stress, even if the car's engine (the cancer) is still ticking.
• The Explanation: ERAS might not stop the cancer cells from hiding, but it stops the surgery from weakening the body so much that the patient can't fight off other issues or tolerate the next round of treatment (chemotherapy). It keeps the "engine" running strong enough to survive the long haul.

The Bottom Line

This paper is like a report card for a new way of managing surgery. It tells us that Enhanced Recovery After Surgery (ERAS) is a game-changer.

It's not just a "nice-to-have" for getting patients out of the hospital faster. It is a critical tool that actually helps colorectal cancer patients live longer. However, to get that extra longevity, hospitals need to be disciplined: they must follow the protocol strictly (like a pit crew following a checklist) and ensure patients get the full benefit of the "fast-track" recovery.

In short: If you or a loved one needs colorectal cancer surgery, asking for an ERAS protocol isn't just about a quicker discharge; it's about giving the body the best possible chance to survive the next five years and beyond.

Technical Summary

1. Problem Statement

Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide, with surgery remaining the primary curative treatment. While Enhanced Recovery After Surgery (ERAS) protocols are well-established for improving short-term outcomes (e.g., reduced complications, shorter hospital stays, faster recovery), their impact on long-term oncological survival remains controversial. Previous literature presents conflicting data: some studies suggest ERAS improves survival by reducing inflammation and facilitating adjuvant therapy, while others indicate no prognostic benefit. There is a critical need to synthesize high-quality evidence to determine if perioperative ERAS protocols influence long-term Overall Survival (OS) and Disease-Free Survival (DFS) in CRC patients.

2. Methodology

The study adhered to the PRISMA 2020 guidelines and followed a pre-registered protocol (PROSPERO CRD42024618247).

• Data Sources: A comprehensive search was conducted across PubMed, Web of Science, Embase, Medline Ovid, and Cochrane Library from January 1, 1995, to December 31, 2025.
• Inclusion Criteria:
  • Population: Adults (≥18 years) undergoing CRC surgery.
  • Intervention: ERAS protocols (defined as ≥5 core components, e.g., preoperative nutrition, multimodal analgesia, early mobilization).
  • Comparator: Conventional perioperative care.
  • Outcomes: Long-term survival data (OS ≥12 months, DFS) with extractable Hazard Ratios (HR) or Kaplan-Meier (KM) curves.
  • Study Types: Randomized Controlled Trials (RCTs) and prospective/retrospective cohort studies.
• Data Extraction & Quality Assessment:
  • Two independent reviewers extracted data.
  • Quality Control: RCTs were assessed using the Cochrane Risk of Bias 2.0 tool; Cohort studies were evaluated using the Newcastle-Ottawa Scale (NOS). All included studies scored 6–9 (moderate to high quality).
• Statistical Analysis & Innovation:
  • KM Curve Reconstruction: To overcome the lack of individual patient data (IPD), the authors utilized a validated two-step method: digitizing published KM curves using Origin Pro 2024 and reconstructing individual survival data using the Shiny-KM web application (based on Guyot et al.'s algorithm).
  • Meta-Analysis Models: Both KM-based meta-analysis (10 studies, 5,867 patients) and aggregated data meta-analysis (8 studies, 5,556 patients) were performed to cross-validate results.
  • Heterogeneity: Assessed via Cochran's Q and $I^2$ statistics. Random-effects models were used for high heterogeneity ($I^2 > 50\%$); otherwise, fixed-effects models were applied.
  • Subgroup Analyses: Stratified by tumor stage (Stage I-II vs. III-IV) and ERAS adherence levels (High ≥70% vs. Low <70%).

3. Key Contributions

• First Large-Scale Long-Term Survival Synthesis: This is one of the most comprehensive meta-analyses to date specifically addressing the long-term survival impact of ERAS in CRC, encompassing nearly 6,000 patients.
• Methodological Rigor: The study employed advanced statistical techniques to reconstruct individual patient data from published KM curves, allowing for a more precise estimation of survival probabilities and hazard ratios than traditional aggregate-data meta-analyses.
• Adherence-Outcome Correlation: It explicitly quantifies the relationship between protocol compliance and survival, establishing a threshold (≥70% adherence) for clinical benefit.
• Stage-Specific Insights: It differentiates the survival benefits based on tumor staging, highlighting that early-stage patients derive the most significant advantage.

4. Key Results

• Overall Survival (OS):
  • ERAS significantly improved OS at all time points compared to conventional care:
    • 1-Year: 93.2% (ERAS) vs. 90.2% (Control)
    • 2-Year: 86.7% vs. 81.3%
    • 3-Year: 81.1% vs. 72.4%
    • 5-Year: 70.9% vs. 60.6%
  • Mortality Risk: The pooled Hazard Ratio (HR) for mortality was 0.72 (95% CI: 0.63–0.83, $P < 0.01$), indicating a 28% reduction in long-term mortality for patients in the ERAS group.
• Disease-Free Survival (DFS):
  • No statistically significant difference was observed between ERAS and control groups (HR = 0.90, 95% CI: 0.68–1.19, $P = 0.45$). The authors attribute this to limited sample size in DFS-specific studies, heterogeneity in DFS definitions, and the fact that ERAS primarily enhances surgical safety rather than directly preventing recurrence.
• Subgroup Analysis:
  • Tumor Stage: Patients with Stage I-II tumors showed a significantly greater survival benefit (HR = 0.61) compared to Stage III-IV.
  • ERAS Adherence: High adherence (≥70%) was associated with a 38% reduction in mortality risk (HR = 0.62) compared to low adherence.
• Publication Bias: Funnel plots indicated symmetry, suggesting a low likelihood of publication bias.

5. Significance and Clinical Implications

• Paradigm Shift: The findings challenge the historical view that ERAS is solely a short-term recovery tool. The study provides robust evidence that ERAS is a critical component of comprehensive cancer care that directly influences long-term survival.
• Mechanism of Action: The survival benefit is likely driven by a synergistic effect: reduced surgical stress/inflammation, preservation of immune function, and the facilitation of timely adjuvant chemotherapy (initiated 2–3 weeks earlier in ERAS patients).
• Implementation Strategy: The data underscores that compliance is paramount. Merely adopting an ERAS protocol is insufficient; achieving ≥70% adherence to core measures is essential to realize the survival benefits.
• Future Directions: The study calls for large-scale RCTs with standardized DFS definitions and the integration of molecular profiling (e.g., single-cell sequencing) to further elucidate the immunological mechanisms linking ERAS to long-term survival.

Conclusion: Perioperative ERAS protocols significantly enhance 1- to 5-year overall survival and reduce long-term mortality in colorectal cancer patients, particularly for those with early-stage disease and high protocol adherence. These findings support the mandatory integration of high-compliance ERAS pathways into standard CRC surgical care.